Allergy Thera. Share News (AGY)

UK shareholder meetings calendar - next 7 days

IN BRIEF: Allergy Therapeutics treats first patient in allergy trial

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Treats its first patient in the third phase of its paediatric trial of Grass Mata MPL. The trial aims to evaluate the long-term efficacy and safety of the drug in treating children with grass pollen allergies. The drug was trialled in adults last year, and showed a "highly statistically significant reduction in the combined symptom and medication score". Grass Mata MPL addresses the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen, and works to modify the body's allergic response in as few as six injections ahead of the allergy season.

LONDON MARKET MIDDAY: Stocks up after Donald Trump's shock victory

(Alliance News) - Stock prices in London remained higher at midday on Wednesday as markets digested the surprisingly speedy news that Donald Trump, along with policies likely to stoke higher inflation, will be re-entering the White House.

Allergy Therapeutics annual loss narrows thanks to reduced expenses

(Alliance News) - Allergy Therapeutics PLC on Wednesday said it narrowed its loss during its most recent financial year despite a decline in revenue, as it reduced administrative expenses.

Allergy Therapeutics shares surge as enters into secured loan facility

(Alliance News) - Allergy Therapeutics PLC shares rallied on Wednesday after it announced a funding update with an alternative asset management firm.

LONDON MARKET MIDDAY: FTSE 100 stays green as Bunzl bumps guidance

(Alliance News) - Stock prices in London were predominantly higher on Tuesday, as the FTSE 100 enjoyed a boost from bumper Bunzl guidance, and a strong start from resource firms.

AIM WINNERS & LOSERS: Belluscura shares up on expected revenue boost

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

Allergy Therapeutics secures cash to see it through September

(Alliance News) - Allergy Therapeutics PLC shares fell on Tuesday, despite securing an additional GBP5 million in loans, extending its cash runway.

TRADING UPDATES: Croma Security trading well; Fonix to up final payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Allergy Therapeutics welcomes peanut allergy vaccine trial results

(Alliance News) - Allergy Therapeutics PLC on Monday hailed positive findings from trial results for a peanut allergy vaccine.

TRADING UPDATES: Abingdon Health buys IVDeology Holdings

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Allergy Therapeutics starts dosing patients in peanut allergy trial

(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.